Akums Drugs and Pharmaceuticals IPO: Akums Drugs and Pharmaceuticals Limited, a leading name in the Indian pharmaceutical industry, is set to launch its Initial Public Offering (IPO) on July 30, 2024, closing on August 1, 2024. The IPO aims to raise approximately ₹1,856.74 crores through a combination of fresh issues and an offer for sale (OFS).
Akums Drugs and Pharmaceuticals IPO Structure and Key Dates
- Issue Open Date: July 30, 2024
- Issue Close Date: August 1, 2024
- IPO Size: Approx ₹1,856.74 crores
- Fresh Issue: ₹680.00 crores
- Offer for Sale: 17,330,435 equity shares
- Face Value: ₹2 per equity share
- Price Band: ₹646 to ₹679 per share
- Listing: BSE and NSE
- Retail Quota: 10%
- Qualified Institutional Buyers (QIB) Quota: 75%
- Non-Institutional Investors (NII) Quota: 15%
Kotak NIFTY Midcap 50 Index Fund NFO
Akums Drugs and Pharmaceuticals IPO GMP Date Wise
| Date | IPO GMP |
| 26 July 2024 | ₹150 |
| 25 July 2024 | ₹150 |
Akums Drugs and Pharmaceuticals IPO Market Lot and Application
The minimum market lot for retail investors is 22 shares, requiring an application amount of ₹14,938. Retail investors can apply for up to 13 lots, totaling 286 shares at ₹194,194.
- Retail Minimum Lot: 22 shares (₹14,938)
- Retail Maximum Lot: 286 shares (₹194,194)
- S-HNI Minimum Lot: 308 shares (₹209,132)
- B-HNI Minimum Lot: 1,474 shares (₹1,000,846)
Akums Drugs and Pharmaceuticals IPO Allotment and Listing Schedule
- Basis of Allotment: August 2, 2024
- Refunds: August 5, 2024
- Credit to Demat Accounts: August 5, 2024
- Listing Date: August 6, 2024
Company Overview
Established in 2004, Akums Drugs is a prominent contract development and manufacturing organization (CDMO) in India, offering a wide range of pharmaceutical products and services. The company holds intellectual property rights for various manufacturing processes and provides end-to-end development and manufacturing solutions. Their offerings include formulation R&D, regulatory dossier preparation, and testing services. Akums also manufactures and sells branded pharmaceutical formulations and active pharmaceutical ingredients (APIs)
Akums is the largest India-focused CDMO by revenue, production capacity, and clients served in FY2023, with a 30.2% market share in the Indian domestic CDMO market as of FY2024
Financial Performance
- FY2022: Revenue of ₹3,694.52 crores, PAT of ₹-250.87 crores
- FY2023: Revenue of ₹3,700.93 crores, PAT of ₹97.82 crores
- FY2024: Revenue of ₹4,212.21 crores, PAT of ₹0.79 crores
Objectives of the Akums Drugs and Pharmaceuticals IPO
The proceeds from the IPO will be utilized for:
- Repayment/prepayment of indebtedness
- Funding incremental working capital requirements
- Pursuing inorganic growth through acquisitions
- General corporate purposes
This IPO provides an opportunity for investors to participate in the growth story of a leading CDMO with a strong market presence and extensive product portfolio.